Metastatic Prostate Cancer at Diagnosis in Decline


Early detection of prostate cancer (PCa) in the United States has resulted in a decrease in the number of men presenting with metastatic PCa, investigators concluded in a presentation of study findings at the 33rd European Association of Urology Congress in Copenhagen, Denmark.

In an analysis of data from the Surveillance, Epidemiology and End Results (SEER) program, Thomas Helgstrand, MD, PhD, of the Copenhagen Prostate Cancer Center, and colleagues found that the incidence of de novo metastatic PCa declined from 12.0 cases per 100,000 men in 1980-1984 to 4.4 cases per 100,000 men in 2005-2011

The results from this population-based analysis indicate that early detection identifies patients with PCa at an earlier time in the course of the disease and to an increasing extent before patients have developed metastatic disease. An unwanted consequence of this earlier detection, however, is overdiagnosis and overtreatment of men harbouring non-lethal localized prostate cancer whose remaining length of life would be unchanged and whose quality of life would possibly be greater if not diagnosed at all.


Helgstrand JT, Klemann N, Toft BF, et al. Incidence- and survival trends of de-novo metastatic prostate cancer: A population based analysis of two national cohorts from USA and Denmark. Data presented at the 33rd European Association of Urology Congress in Copenhagen, Denmark.

Send me a message if you have any question or make an appointment (toll-free: 800444444 or +971 4 520 0500)

Emirates Hospital, Jumeirah Beach Road, opposite Jumeirah Park (below the Dubai Canal Bridge Take the U-turn under the bridge to reach the entrance) - Dubai